Antimalarial activity against Plasmodium vinckei petteri infected mice (Mus musculus) at 13 mg/kg/day, peroral administered 4 days after infection for 4 days
Antimalarial activity against Plasmodium vinckei petteri infected mice (Mus musculus) at 5 mg/kg/day, peroral administered 4 days after infection for 4 days
Antimalarial activity against Plasmodium vinckei petteri infected in CD mice (Mus musculus) assessed as inhibition of parasitaemia at 1 mg/kg, intraperitoneal daily for 4 days measured on day 5
Antimalarial activity against Plasmodium vinckei petteri infected in CD mice (Mus musculus) assessed as inhibition of parasitaemia at 10 mg/kg, intraperitoneal daily for 4 days measured on day 5
Antimalarial activity against Plasmodium vinckei petteri infected in CD mice (Mus musculus) assessed as inhibition of parasitaemia at 20 mg/kg, intraperitoneal daily for 4 days measured on day 5
Antimalarial activity against Plasmodium vinckei petteri infected in CD mice (Mus musculus) assessed as inhibition of parasitaemia dosed daily for 4 days measured on day 5
Antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse assessed as reduction in parasitemia administered once daily via intraperitoneal route starting from day 1 to day 4 post infection measured on day 5 Giemsa staining based flow cytometric analysis
Antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse assessed as reduction in parasitemia at 20 mg/kg, ip once daily for 4 consecutive days starting from day 1 to day 4 post infection and measured on day 5 Giemsa staining based flow cytometric analysis
Antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse assessed as reduction in parasitemia administered once daily via oral gavage starting from day 1 to day 4 post infection measured on day 5 Giemsa staining based flow cytometric analysis
Antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse assessed as reduction in parasitemia at dosed intraperitoneally once daily for 4 consecutive days starting from day 1 to day 4 post infection and measured on day 28 by Giemsa staining based flow cytometric analysis
Selectivity index, ratio of ED50 for antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse administered via intraperitoneal route to ED50 for antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse administered via oral route
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 50 mg/kg/day, ip measured on day 4 postinfection
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 100 mg/kg/day, ip measured on day 5 postinfection
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 1 mg/kg/day, po measured on day 4 postinfection
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 50 mg/kg/day, po measured on day 4 postinfection